Notwithstanding promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These https://louiseuqyg489252.blogdomago.com/40481464/the-drug-faces-is-dealing-with-pbm-hurdles-the-review-of-access-disputes